Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Безопасность применения, эффективность и степень удовлетворения родителей назальным аспиратором Отривин Бэби при лечении заложенности носа у детей
Безопасность применения, эффективность и степень удовлетворения родителей назальным аспиратором Отривин Бэби при лечении заложенности носа у детей
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Clement PAR, Bluestone CD, Gordts F et al. Management of rhinosinusitis in children: Consensus Meeting, Brussels, September 13, 1996. Arch Otolaryngol Head Neck Surg 1998; 124: 31–4.
2. Faden HS. Immunology of the middle ear: role of local and systemic antibodies in clearance of viruses and bacteria. Ann N Y Acad Sci 1997; 830: 49–61.
3. Bernstein JM, Faden HF, Dryja DM, Wactawski-Wende J. Microecology of the nasopharyngeal bacterial flora in otitis-prone e non otitis-prone children. Acta Otolaryngol 1993; 113: 88–92.
4. Garcia-Rodriguez JA, Fresnadillo Martinez MJ. Dynamics of nasopharyngeal colonisation by potential respiratory pathogens. J Antimicrob Chemiother 2002; 50 (Suppl. S2): 59–73.
5. Harrison LM, Morris JA, Telford DR et al. The nasopharyngeal bacterial flora in infancy: effects of age, gender, season, viral upper respiratory tract infection and sleeping position. FEMS Immunol Med Microbiol 1999; 25: 19–28.
6. Veenhoven RH, Bogaert D, Shilder AG et al. Nasopharyngeal pneumococcal carriage after combined pneunococcal conjugate and polysaccharide vaccination in children with a history of recurrent AOM. Clin Infect Dis 2004; 39: 911–9.
7. Marchisio P, Claut L, Rognoni A et al. Differences in nasopharyngeal bacterial flora in children with nonsevere recurrent AOM and COME: implications for management. Pediatr Infect Dis J 2003; 22: 262–8.
8. Principi N, Passali D. Fisiopatologia rinosinusale nelbambino. Pavia: EDIMES; 1998.
9. Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002; 112: 4S–12S.
10. Parkin PC, Taylor CY, Petric et al. Controlled study of respiratory viruses and wheezing. Arch Dis Child 2002; 87: 221–2.
11. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144–54.
12. Venelle M, Brander PE, Kingshott RN et al. Is there a familial association between obstructive sleep apnoea/hypopnoea and the sudden infant death syndrome? Thorax 2004; 59: 337–41.
13. Ghelfi D. Sleep apneas in children. Ther Umsch 2000; 57: 463–6.
14. Gruppo di lavoro sui farmaci pediatrici (istituito presso l’AIFA) Decongestionanti nasali: nei bambini i rischi superano i benefici. Medico e Bambino 2007; 26: 309.
15. Smith MBH, Feldman W. Over the counter cold medication: a critical review of clinical trials between 1950 and 1991. JAMA 1993; 269: 2258–63.
16. Taverner D, Latte J. Nasal decongestionants for the common cold. Cochrane Database Syst Rev 2007; 1.
17. Seppey M, Krayenbuhl M, Simmen D et al. Rhinomer pour la thérapie de la pathologie rhinosinusale. ORL Highlights 1995; 2: 20–4.
18. Traissac L, Bordenave L, Bareille R et al. In vitro study of the effect of sea water by-products in the respiratory mucosa. Rev Soc Fr ORL 1995; 32.
19. Tabary O, Muselet C, Yvin JC et al. Physiomer reduces the chemokine interleukin-8 production by activated human respiratory epithelial cells. Eur Respir J 2001; 18: 1–6.
2. Faden HS. Immunology of the middle ear: role of local and systemic antibodies in clearance of viruses and bacteria. Ann N Y Acad Sci 1997; 830: 49–61.
3. Bernstein JM, Faden HF, Dryja DM, Wactawski-Wende J. Microecology of the nasopharyngeal bacterial flora in otitis-prone e non otitis-prone children. Acta Otolaryngol 1993; 113: 88–92.
4. Garcia-Rodriguez JA, Fresnadillo Martinez MJ. Dynamics of nasopharyngeal colonisation by potential respiratory pathogens. J Antimicrob Chemiother 2002; 50 (Suppl. S2): 59–73.
5. Harrison LM, Morris JA, Telford DR et al. The nasopharyngeal bacterial flora in infancy: effects of age, gender, season, viral upper respiratory tract infection and sleeping position. FEMS Immunol Med Microbiol 1999; 25: 19–28.
6. Veenhoven RH, Bogaert D, Shilder AG et al. Nasopharyngeal pneumococcal carriage after combined pneunococcal conjugate and polysaccharide vaccination in children with a history of recurrent AOM. Clin Infect Dis 2004; 39: 911–9.
7. Marchisio P, Claut L, Rognoni A et al. Differences in nasopharyngeal bacterial flora in children with nonsevere recurrent AOM and COME: implications for management. Pediatr Infect Dis J 2003; 22: 262–8.
8. Principi N, Passali D. Fisiopatologia rinosinusale nelbambino. Pavia: EDIMES; 1998.
9. Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002; 112: 4S–12S.
10. Parkin PC, Taylor CY, Petric et al. Controlled study of respiratory viruses and wheezing. Arch Dis Child 2002; 87: 221–2.
11. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144–54.
12. Venelle M, Brander PE, Kingshott RN et al. Is there a familial association between obstructive sleep apnoea/hypopnoea and the sudden infant death syndrome? Thorax 2004; 59: 337–41.
13. Ghelfi D. Sleep apneas in children. Ther Umsch 2000; 57: 463–6.
14. Gruppo di lavoro sui farmaci pediatrici (istituito presso l’AIFA) Decongestionanti nasali: nei bambini i rischi superano i benefici. Medico e Bambino 2007; 26: 309.
15. Smith MBH, Feldman W. Over the counter cold medication: a critical review of clinical trials between 1950 and 1991. JAMA 1993; 269: 2258–63.
16. Taverner D, Latte J. Nasal decongestionants for the common cold. Cochrane Database Syst Rev 2007; 1.
17. Seppey M, Krayenbuhl M, Simmen D et al. Rhinomer pour la thérapie de la pathologie rhinosinusale. ORL Highlights 1995; 2: 20–4.
18. Traissac L, Bordenave L, Bareille R et al. In vitro study of the effect of sea water by-products in the respiratory mucosa. Rev Soc Fr ORL 1995; 32.
19. Tabary O, Muselet C, Yvin JC et al. Physiomer reduces the chemokine interleukin-8 production by activated human respiratory epithelial cells. Eur Respir J 2001; 18: 1–6.
Авторы
М.Касати1, М.Пикка1, Р.Маринелло1, Дж.Квартароне2
1Департамент постоянной подготовки семейных педиатров, FIMP Ломбардия;
2Департамент медицинских дел, Новартис СН, Ориджио, Варезе, Италия
1Департамент постоянной подготовки семейных педиатров, FIMP Ломбардия;
2Департамент медицинских дел, Новартис СН, Ориджио, Варезе, Италия
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.